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Mary Laughlin,1 Joanne Kurtzberg,2 John McMannis,3 Lawrence Petz4The Eighth Annual International Cord Blood
Transplantation Symposium was presented by the
Cord Blood Forum in San Francisco June 3-5, 2010.
It was partially supported by unrestricted educational
grants from StemCyte International Cord Blood Cen-
ter, the National Marrow Donor Program (NMDP),
and Tarix Pharmaceuticals. The Symposium was also
partially financially supported by a contract between
the Health Resources and Services Administration
(HRSA), U.S. Department of Health and Human Ser-
vices, and the Cord Blood Forum. Any opinions, find-
ings, conclusions, or recommendations expressed or
presented at this conference are those of the presenters
and do not necessarily reflect the views of the U.S.
Government.
The 39-member faculty for the Symposium in-
cluded leaders of the major transplantation centers
from the United States, Spain, Germany, Taiwan,
France, and the Netherlands. Attendees were from
Argentina, Australia, Austria, Bolivia, Brazil, Canada,
Chile, Colombia,Denmark, Ecuador, Finland, France,
Germany, Greece, Hong Kong, India, Israel, Italy,
Japan, Korea, Malaysia, Mexico, New Zealand,
Panama, Poland, Portugal, Qatar, Saudi Arabia,
Singapore, Spain, Sweden, Switzerland, Taiwan, the
Netherlands, UnitedKingdom,United ArabEmirates,
and the United States.
The program was divided into 9 sessions. The
sessions on the first day concerned Cord Blood and
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erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.10.007were devoted to Cord Blood and Hematopoietic Stem
Cell Transplantation. Sessions were as follows: (I) Basic
Science and Preclinical Studies, (II) Emerging Uses of
Cord Blood in Hematology and Regenerative Medi-
cine, (III) Clinical Results: Comparisons of CBT
with Related and Unrelated Donor Transplants, (IV)
Indications and Conditioning Regimens for HSCT,
(V) New Concepts in Donor-Recipient Matching for
CB Transplants, (VI) Engraftment of Cord Blood
Stem Cells, (VII) Infections, Immune Reconstitution
and Adoptive Immunotherapy after Cord Blood
Transplantation, (VIII) HSCT for Sickle Cell Disease,
Thalassemia and HIV-Infected Patients, (IX) Cord
Blood Banking.CORD BLOOD (CB) AND REGENERATIVE
MEDICINE
Session IA. Basic Science and Preclinical Studies
Dr. Hal Broxmeyer delivered the Keynote address:
‘‘Cryopreserved cord blood for hematopoietic stem
cells, IPS cells, and other nonhematopoietic cells, their
regulation, and potential for regenerative medicine.’’
He pointed out that a study in 2003 demonstrated
high-efficiency recovery of functional hematopoietic
progenitor and stem cells from human CB cryopre-
served for 15 years. After thawing, there was .80%
recovery of hematopoietic progenitor cells, and their
proliferative capacity was intact. A more recent study
after cryopreservation for up to 24 years indicates
high-efficiency recovery of colony forming unit-
granulocyte macrophage (CFU-GM) and colony
forming unit-granulocyte, erythrocyte, monocyte,
megakaryocyte (CFU-GEMM). Also, CD341 cells
manifested primary and secondary engraftment of
nonobese diabetic/severe combined immunodefi-
ciency (NOD/SCID) IL-2 Rynull mice. Recent studies
by a number of investigators have demonstrated that
induced pluripotent stem (iPS) cells can be generated
from CB. Preclinical studies using a mouse hind-
limb ischemia model focused on a role for myeloid
Biol Blood Marrow Transplant 17:176-189, 2011 177Eighth Annual International UBCB Transplantation Symposiummacrophage lineage cells with a myeloid-derived sup-
pressor (MDSC) phenotype of Gr11CD11b1cells,
because these cells have been reported to regulate tu-
morigenesis through induction of angiogenesis. Data
derived from studies using this model indicate that
Gr1dimCD11b1 cells within skeletal muscle are in-
creased in the context of ischemia. Further, that
astrocyte-plexus was formed from muscle-derived
Gr1dimCD11b1cells in Matrigel culture, followed by
formation of isolectin and von Willebrand Factor
(vWF)-expressing cells, similar to that reported for an-
giogenesis in the retina. Finally, injection of these cells
into ischemic muscle was associated with significantly
enhanced recovery of blood flow, and these cells incor-
porated into vessel cells. However, it remains to be de-
termined whether Gr1dimCD11b1–like cells can be
found in or generated fromCB or other human tissues,
and whether they can be used for human regenerative
medicine.
Other studies relate to the enhancement of the ef-
fectiveness of HSC transplantation. It has been shown
that inhibition of CD26 in human CB CD341 cells
enhances their engraftment of NOD/SCID mice. In
adult patients with malignancy, CD26/DDPOV inhi-
bition was used to enhance engraftment to single CB
unit transplantation. Further studies demonstrated
that overexpression of Rheb2 enhances mouse hema-
topoietic progenitor cell growth while impairing
stem cell repopulation. Overall conclusions regarding
the experiments with Rheb2 led to the identification
of a pathway that was important in expansion of
immature progenitor/stem cells in vitro and in vivo;
however, this expansion is accompanied by a loss of
activity. Thus, means of regulating the activity of the
Rheb-mTOR pathway may be effective at expansion
without loss of repopulating ability. Finally, recent
studies indicate that up-regulation of nascent mito-
chondrial biogenesis in mouse hematopoietic stem
cells parallels up-regulation of CD34 and loss of pluri-
potency, which suggests a potential strategy for reduc-
ing oxidative risk in stem cells.
Dr. Peter Wernet reported on the production and
uses of unrestricted somatic stem cells (USSC) from
human CB. He pointed out the proof of the biologic
existence of USSC at the clonal level and their in vitro
differentiation potential into 3 germ layers. The cells
have a normal karyotype and can be separated from
mesenchymal stem cells (MSC). USSC lack expression
of the pluripotency markers Oct4 and NANOG,
which are found in MSC. Osteo-, chondro-, and
fat-cell differentiation of USSC can be demonstrated
in vitro and in vivo. It is clear that these cells are an
early mesodermal cell type. A preimmune fetal sheep
model was used to demonstrate the contribution to or-
ganogenesis of USSC. Single-cell polymerase chain
reaction (PCR) analyses excluded the contribution of
cell fusion to formation of the human liver parenchymacells in this model. Also demonstrated in this model
was the in vivo differentiation of USSCs into cardo-
myocytes and Purkinje cells. Using a pig model of
acute myocardial infarction, functional improvement
and prevention of scar formation was demonstrated
after transplant of USSC. The function of USSC
may not be the cell repopulation effect, but it may be
an effect that triggers the autonomous regenerative
capacity of an organ. Also, USSCs from human umbil-
ical CB can be differentiated into neurons with a dopa-
minergic phenotype.
Dr. Paul Sanberg indicated that bone marrow (BM)
and CB stem cells can be transformed into cells with
neural markers and glial markers. Major neurologic
diseases in which treatment using cell therapy has
been studied include Parkinson’s disease, stroke, Hun-
tington’s disease, traumatic brain injury, spinal cord
injury, amyotrophic lateral sclerosis (ALS), and Alz-
heimer’s disease. CB has advantages over BM stem
cells, including that they are easier to obtain with no
harm to mother or infant. About one-third of patients
with stroke have a chronic deficit, and animal models
of stroke have been developed. In a rat model, cells
were injected intravenously, and functional improve-
ment was demonstrated in an acute stroke model.
Some cells were found in the brain but not enough
were demonstrated to indicate that cell replacement
provided the therapeutic benefit. The optimal cell
dose is difficult to determine as is the optimal time
poststroke. The most significant effect occurred at 48
hours poststroke. In addition to stem cells, monocytes
may significantly contribute to neovascularization in
heart and other ischemic diseases. Removal of mono-
cytes inhibited the effectiveness of CB in treatment
of stroke. Cerebral palsy is a brain injury in children
that develops for various reasons. A cerebral palsy
model has been developed in addition to the human
studies currently in progress.Session IB. Basic Science and Preclinical Studies
Dr. Juan Carlos Izpisua Belmonte discussed ‘‘iPS
cells from cord blood.’’ A number of important steps
must be accomplished prior to use of iPS cell therapy
in humans. Issues include the derivation of human
iPS cells (genetic correction, safe protocols, efficient
protocols, clinical-grade lines), specific differentiation
protocols (differentiation ability of iPS cells, directed
differentiation protocols), tissue engineering and
animal models, and clinical-grade protocols and
manufacturing steps to develop a stem cell product.
This is a long journey, and we are at the beginning
of that journey. iPS cells, when injected into mice, pro-
duce tumors. Reprogramming can be accomplished
with numerous cell types, although a number of inves-
tigators have pointed out that CB stem cells offer ad-
vantages over other types of cells. iPS cells are now
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have been generated under registration at Stem Cell
Bank, Barcelona. Further investigations have led to
the conclusions that (1) CB cells are readily available,
are young cells (minimizing the risk of having accumu-
lated mutations), and are already banked along with
immunologic information; (2) CB CD1331 cells can
be reprogrammed with only 2 factors (Sox2 and
Oct4); (3) CB cells are properly reprogrammed into
pluripotent stem cells from both the expression and
the epigenetic point of view; (4) CB iPS can be differ-
entiated into cardiomyocytes, dopaminergic neurons,
and hematopoietic CD341 cells; and (5) CB may con-
stitute healthy, off-the shelf, immunologically compat-
ible cells to establish iPS cell lines for future therapy.
Dr. Linzhao Cheng discussed the derivation and dif-
ferentiation potential of human iPS cells from CB.
Human embryonic stem (ES) cells provide an unlim-
ited source of human cells, have the potential to form
any cell types, provide a possibility for gene targeting,
and create genetic models from human developmental
biology or human diseases. However, there are ethical
issues with human embryos, and there are only a lim-
ited number of lines and they are allogeneic. Human
iPS cell lines are highly similar to human ES cells. Hu-
man blood-derived iPS cells can differentiate into var-
ious cell types as is true with human ES cells: (1) they
can generate CFU/(erythroid burst-forming units)
BFU-E hematopoietic progenitor cells as well as
more mature neutrophils, monocytes/macrophages,
and nucleated erythroid cells; (2) they can generate
multiple types of vascular cells such as endothelial cells
and smooth muscle cells; (3) they can be expanded un-
der a xeno-free culture condition and differentiate into
neural stem cells and dopaminergic neurons; and (4)
they can differentiate into cardiomyocytes and hepato-
cytes. A goal is to develop advanced gene and cell ther-
apy (AGCT). Gene correction of recessive mutations
in human iPS cell lines requires the following: the
use of existing lentivector (clinical grade) expressing
an extra copy of the CYBB gene that is inserted ran-
domly, allowing clonal analysis from iPS all the way
to neutrophils; targeted gene correction, by either cor-
recting the mutation in situ or by inserting a minigene
downstream of the ATG start codon; targeted gene ad-
dition of a CYBB minigene at a nonpathogenic ‘‘safe-
harbor’’ locus, if it is much more efficient.
Dr. Mariusz Z Ratajczak discussed CB-derived very
small embryonic-like stem cells. BM is the ‘‘home’’ not
only of hematopoietic stem cells but data indicate that
a population of germ line/epiblast-derived pluripotent
very small embryonic-like (VSEL) stem cells reside in
BM as well as in other organs.
VSEL stem cells could be released/mobilized from
neonatal BM (and other niches?) and circulate in neo-
natal peripheral blood (CB). As in murine BM-derived
VSELs, human umbilical CB (UCB)-derived CD45-negative VSELs could correspond to a population of
the most primitive, long-term repopulating HSC
(LT-HSC). Of note, currently employed routine
UCB processing strategies may lead to an unwanted
loss of up to 50% of these small cells that are en-
dowed with such remarkable hematopoietic activity.
The neural and cardiac differentiation of VSELs is
currently being explored.Session IIA. Emerging Uses of CB in
Hematology and Regenerative Medicine
Dr. Joanne Kurtzberg discussed the status of a clini-
cal trial of autologous CB stem cells for the treatment
of cerebral palsy (CP) and other acquired brain in-
juries. Autologous unrelated cord blood transplanta-
tion (UCBT) is being used in experimental protocols
to treat CP, hypoxic ischemic encephalopathy (HIE),
congenital hydrocephalus, and other brain injuries.
Animal models have demonstrated improvement in
neurologic status after infusions. To date, 198 infu-
sions have been done in 184 patients: 76% for cerebral
palsy, 12% for congenital hydrocephalus, and 12% for
other injuries. CBs accepted for infusions have a total
nucleated count (TNC) of $1  107 cells/kg, have
negative bacterial cultures and maternal infectious dis-
ease markers, and confirmed identity (HLA). The in-
fusions have been well tolerated, and no clinically
apparent infections have been noted. Efficacy has
been very hard to determine because of placebo effects.
There are many positive anecdotes, leading to impres-
sions of benefit in babies with severe HIE and congen-
ital hydrocephalus. Also, there are impressions of
benefit in children with mild to moderate CP. A ran-
domized trial is needed to answer the question of ben-
efit, and such a trial is being developed; outcomes can
be expected in about 2.5 years. Interim conclusions
are: (1) infusion of autologous UCB is safe and feasible
in young children with acquired neurological disor-
ders; (2) quality parameters of CB units (CBUs) stored
at private banks are inferior to those stored at public
banks (at present, only 14% of private units would
qualify for listing as a high-quality unit in the national
CB bank Inventory [NCBI])’ and (3) if autologous
UCB infusion is determined to be clinically effica-
cious, the quality of privately banked CBUs should
be held to the same standards as publicly banked units.
Dr. Wise Young discussed progress in development
of treatment of spinal cord injuries (SCIs) with CB
stem cells. SCI usually involves a contusion of the spi-
nal cord; relatively few SCI have penetrating wounds.
An animal model has been developed using a weight
dropped on the spinal cord from a defined height.
Regenerative therapy for SCI involves bridging the
gap with a loose matrix of glial cells and inflammatory
cells to fill the injury site. Many axons grow into the
site but do not grow out the other side. Axons grow
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support is necessary for long tract regeneration. Block-
ing growth inhibitors is also necessary and can be
accomplished with antibodies and chondroitinase.
Treatment of SCI by intravenous infusion of human
umbilical cord blood mononuclear cells (UCBMC)
has been shown to improve locomotor recovery after
clip compression of the rat spinal cord and contused
rat cords. Intraspinal UCBMC improves locomotor
recovery in hemisected rats and the contused rat spinal
cord. A large study network has been developed in
China, the ‘‘China SCI Network.’’ Several trials are
planned: an observational trial with 500 subjects with
chronic SCI; a phase 1 lithium trial with 20 subjects
with chronic SCI; a phase 2 oral lithium trial (in China)
with 40 subjects randomized to lithium or placebo;
a phase 2mononuclear cell transplant trial with 20 sub-
jects; and a phase 3 UCBM cell transplants 6 lithium
with 400 subjects with chronic SCI. Trials of intra-
dural decompression in over 700 patients with
subacute spinal cord injury have shown beneficial re-
sults. A multicenter phase 3 trial is planned to compare
laminectomy alone against laminectomy and intra-
dural decompression. If shown to be beneficial, this
procedure provides an unprecedented opportunity
for surgically controlled trials of cell transplants in
spinal cord injury. In conclusion, UCBMC and lith-
ium are beneficial in animal SCI models; lithium
strongly stimulates UCBMC to proliferate and pro-
duce neurotrophin in vitro and in vivo; lithium also
stimulates neural stem cells to produce neurons, re-
sulting in more gray matter in brains. Protocols are
being developed to test UCBMC and lithium treat-
ment of human chronic spinal cord injury in China
and the United States.
Dr. Shinn-Zong Lin discussed a clinical trial of the
treatment of stroke with CB stem cells. A human clin-
ical trial on chronic stroke is in progress in Taiwan uti-
lizing subcutaneous granulocyte-colony stimulating
factor (G-CSF) injection combined with intracerebral
mobilized peripheral blood hematopoietic stem cells
(CD341) transplantation. Subjects are those with mid-
dle cerebral artery ischemia with a measurable deficit;
subjects must be 35 to 75 years old and have a modified
Rankin scale$1. Data thus far indicate that there is no
remarkable movement of CD341 stem cells in the
brain after implantation. There is regeneration of the
corticospinal tracts, and the motor evoked potential
of regenerated nerves is good. There is improvement
in body motor function recovery after transplantation.Session IIB. EmergingUses of CB inHematology
and Regenertive Medicine
Dr. Grac¸a Almeida-Porada discussed the unique
characteristics of CB stem cells for tissue repair. The
ultimate goal of stem cell therapy is to restore normalfunction of a tissue or organ through the production of
normal cells and/or through the delivery of factors that
decrease inflammation/apoptosis, induction of regen-
eration, or immunomodulation. The ideal cell for
cell therapies should be readily available, autologous,
or nonimmunogenic, have appropriate differentiative
potential, have preferential homing/engraftment to
the target, and must be nontumorigenic. A preimmune
model to assay human HSC has been developed in
sheep and has been used for evaluation of CB-
derived HSC for liver regeneration. Human cells are
transplanted into 45- to 65-day sheep fetuses. Upon
in utero transplantation, endothelial progenitor cells
(EPCs) engraft into the liver (0.12%). Donor-derived
cells preferentially engraft in and around vasculature,
and engrafted cells actively contribute to the liver cy-
toarchitecture through formation of tight junctions,
expression of the hepatocyte marker albumin, pro-
duction of FVIII, and differentiation into Ov61 and
AFP1 liver cells. Additional results indicate that
EPCs engraft in and around the crypts of Lieberk€uhn
(CLR); 23.5% 6 1.7% of the CLR cells are human;
EPCs differentiate into mature intestinal cells at low
percentages (8.1% 6 1.0% of the interstitial cell pop-
ulation) and contribute (\1%) to the enteroendocrine
population. Conclusions are that the unique character-
istics and broad potential of CB-derived stem cells sug-
gest that they may be ideally suited for tissue repair.
CB-derived EPCs constitute a novel and promising
therapy for replenishment of liver and BM vasculature;
EPCs contribute to the intestinal stem cell population
and therefore represent a novel therapy option for in-
testinal disorders and, when transplanted individually
to correct a singular deficit, or in association with other
cells, CB-derived stem cells may be able to correct
more complex diseases involving multiple cell types.
Dr.Mitchell S. Cairo discussed CB stem cells for the
treatment of epidermolysis bullosa (EB). Heritable
forms of EB are a group of mechano-bullous disorders
with skin blistering as a unifying diagnostic feature.
The estimated incidence is1:20,000, there is no eth-
nic or racial predilection, inheritance is either autoso-
mal dominant or recessive, and the clinical severity is
highly variable. The rationale for cell-based therapies
is that the gene of interest is already present in the
genome of a healthy donor, and there is an ability to in-
fuse large numbers of stem cells for long-term engraft-
ment and repopulation and homing to the skin. This
takes advantage of natural properties of adult stem cells
to circulate and home to sites of tissue damage and to
undergo repair of the skin, gastrointestinal (GI) tract,
and esophagus. Advantages of CB as a stem cell source
are that there is no risk to the donor, no donor attri-
tion, immaturity of T cell immunity, a lower incidence
and severity of graft-versus-host disease (GVHD), and
longer telomere length and higher proliferation
potential. BM transplantation in an animal model has
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dystrophic (RD)EB phenotype. An hypothesis is that
allogeneic hematopoietic stem cell transplantation
(HSCT) using reduced-intensity conditioning (RIC)
and family-related donors and unrelated CB donors
will be safe and well tolerated in selected patients
with RDEB. The primary objectives of a study using
allogeneic HSCT are to determine the event-free
survival (EFS) and overall survival (OS) following
RIC consisting of busulfan/fludarabine/alemtuzumab
in selected patients with RDEB.
Dr. Tsuneo A. Takahashi discussed, ‘‘Reevaluation
of factors leading to the successful isolation of MSC
from humanCB and their differentiation tomesenchy-
mal lineages.’’ The objective of this study is to deter-
mine whether CB-MSC are a potential stem cell
source for clinical use. The study will determine the
critical factors regarding successful isolation of CB-
MSC, characterize the high differentiation capability
of the cells to chondrocyte and osteocytes, review their
immunosuppressive activity, seek to develop large-
scale expansion and production of clinical-grade CB-
MSC, and determine the difference between USSC
and CB-MSC. Results thus far indicate that, among
several possible factors for a successful isolation of
CB-MSC, the time between collection and processing
was a decisive factor, and volume was also a critical
factor. Even though the frequency of CB-MSC was
lower initially than BM-MSC, the high proliferation
rate of these cells should allow expansion appropriate
for clinical use. The high proliferation rate combined
with high differentiation capability to chondrocyte
and osteoblast, immunosuppresive activity, and the
karyotype stability after long culture indicate that
CB-MSC should be a potential cell resource for cell
therapy and regenerative medicine.CB AND HSCT
Session III. Clinical Results: Comparisons
of CBTwith Related and Unrelated Donor
Transplants
Dr. Joanne Kurtzberg presented: ‘‘A review of
UCB—Where do we stand?’’ The first CBT was per-
formed in France in 1988, and the success of this trans-
plant opened the whole field of CBT. Related
transplants were the first to be performed, and the first
unrelated transplant was performed in 1993 at Duke
University. The first CB bank was established at the
New York Blood Center in 1992, and at the present
time, more than 20,000 CB transplants have been per-
formed. There are more than 140 CB banks worldwide
and 140,000 cryopreserved units are available in the
United States and .500,000 worldwide. Early success
include the demonstration of less GVHD than with
matched related or unrelated donor transplantation,less stringent HLA matching requirements, increased
access to HSCT for minorities, the establishment of
public banking, and the application to genetic diseases.
Challenges and obstacles include delays in engraft-
ment and graft failure, adequate cell dosing, immune
reconstitution, cost, and funding for public banking.
Potential solutions to some of these problems include
the use of double CBT and/or cell expansion to over-
come inadequate cell dose.
Recently, there has been increased emphasis on
maximizing efficiencies of CB manufacturing with
the goal of producing a high-quality, high-potency
unit. There is increasing emphasis on the end user of
the CB who receives, stores, thaws, and infuses the
product to the patient. Current CBU potency criteria
utilize precryopreservation TNC dose combined
with HLA matching. CFUs provide a more accurate
indication of engraftment probability but the assays
are difficult to standardize among laboratories. How-
ever, assay of ALDHbright cells correlates with results
of CFUs andmay provide amore reproducible assay. A
study is underway to attempt to correlate available pre-
cryopreservation and postthaw data, including TNC,
total mononuclear cell count, CD341, and total
CFU, and to establish a score (‘‘Cord Blood Apgar’’)
to use to predict engraftment. Retrospective data
show an excellent correlation of the precryopreserva-
tion score and engraftment. Future applications of
CB stem cells include extended usage for sickle cell
disease, thalassemia, and autoimmune diseases. Also,
regenerative medicine applications are possible as are
cellular therapies using tissue-specific cells (eg, neural,
pancreatic, endothelial, cardiac). We need to recog-
nize that we still do not know how to best select CB
units for transplantation. More research is necessary
to determine whether double cord transplants are bet-
ter than single CB transplants and whether we can aug-
ment immune reconstitution after CBT. We would
like to have improved strategies for engraftment, im-
mune reconstitution, sickle cell disease, and reduced-
intensity transplants and hope to be successful with
novel applications as for stroke, spinal cord injury, ce-
rebral palsy, neonatal brain injury, and type I diabetes.
Dr. Colleen Delaney discussed, ‘‘Reduced relapse
and similar progression-free survival (PFS) after double-
unit cord blood (DUCB) transplantation: comparison
of outcomes between sibling, unrelated adult, and un-
related DUCB hematopoietic stem cell donors.’’
Cell dose remains the main limitation in offering
UCB transplantation to larger adolescent and adult
patients. To overcome the cell-dose limitation of a sin-
gle-unit UCB unit transplant, double CB transplants
have now been adopted by many transplant centers.
A study has been performed to test the hypothesis
that recipients of double UCB grafts, that otherwise
would have been denied transplant because of inade-
quate cell dose, would have outcomes similar to those
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this 2-center retrospective analysis was to compare
the leukemia-free survival (LFS) of recipients of dou-
ble UCB to those of sibling and unrelated adult volun-
teer donor grafts. Diagnoses were acute myelogenous
leukemia (AML), acute lymphoblastic leukemia
(ALL), chronic myeloid leukemia (CML), and myelo-
dysplastic syndrome (MDS). A total of 536 patients
were studied: 204 5 matched sibling; 152 5 8/8 allele
matched unrelated donor (URD); 52 5 7/8 allele
matchedURD; and 1285 4-6/6HLAmatched double
UCB. Days to neutrophil engraftment for sibling
donors was 16 days, for MUDs was 19 days, and for
DUCB was 26 days. Platelet engraftment was also de-
layed, and \50% of patients had a platelet count
$50,000/mL by day 100. The incidence of grade III-
IV acute GVHD (aGVHD) was lowest in sibling and
DUCB transplants; chronic GVHD (cGVHD) was
also lowest in DUCB transplants. Nonrelapse mortal-
ity (NRM) was highest in DUCB. Relapse was signif-
icantly lower in DUCB compared with other donor
sources (as has been demonstrated in other studies as
well). There was no significant difference in the inci-
dence of LFS among the various donor sources. In
summary, the data from this study indicate similar
LFS with DUCB, sibling, and unrelated adult donors
after myeloablation with a cyclophosphamide/total-
body irridiation (Cy/TBI)-based conditioning. There
is a need to assess the quality of life long term between
donor types, as there is less risk of aGVHD and
cGVHD after DUCB transplantation compared to
unrelated donors.
Dr. Doris Ponce discussed data indicating that pro-
gression free survival (PFS) after cord blood transplan-
tation (CBT) is not different to that after related or
unrelated donor transplantation in patients with hema-
tologic malignancies. A study was performed compar-
ing the 2-year PFS after related donor, unrelated
donor, and DUCB in patients transplanted over the
same time period. A total of 367 patients were included
in the study: 108 related donor transplants, 184 unre-
lated donor transplants, and 75 DUCB transplants.
The incidence of acute leukemia was similar among
the groups, but there was less MDS/CML and more
lymphoid malignancies in DUCB transplants com-
pared to the other donor sources. Neutrophil recovery
after DUCB transplants was delayed after ablative reg-
imens but not after nonmyeloablative regimens; the
speed of neutrophil recovery was similar in all groups
after nonmyeloablative conditioning. The incidence
of aGVHD after DUCB transplants was the same as
unmodified related donor and unrelated donor trans-
plants. Late aGVHD and cGVHD at 1 year was the
same with DUCB transplants as with unmodified
related donor transplants and was lower than with un-
modified unrelated donor transplants. Overall survival
after 2 years after DUCB transplants was not differentfrom other donor sources. Conclusions were that early
mortality after DUCB transplants was compensated
for by reduced late mortality risk so that there was
no difference in 2-year PFS after DUCB transplants
compared to related donor or unrelated donor trans-
plants. Thus, DUCB transplants provide a promising
alternative despite marked HLA mismatch and rela-
tively low cell dose/unit. These data are consistent
with those of the University of Minnesota/Fred
Hutchinson Cancer Research Center study and
Eurocord-Netcord/EBMT studies.
Dr. Vanderson Rocha discussed a comparison of
outcomes after unrelated CBT and matched unrelated
donor reduced intensity conditioning (RIC) transplan-
tation for lymphoid malignancies. A study has been
carried out of patients with malignant lymphoma
(both Hodgkin and non-Hodgkin) and chronic lym-
phocytic leukemia (CLL). A total of 104 patients
from 48 centers were included in the study. Eight-
five percent had an advanced phase of their disease. A
total of 78 patients received a single CBT, and 26 re-
ceived a double CBT. RIC was used for 57% of the
single-unit transplants and 88% of the double CBTs.
Engraftment was 85% with CBT and 97% with pe-
ripheral blood donors. PFS for mantle cell lymphoma
was 75% at 18 months; for indolent non-Hodgkin lym-
phoma was 60% at 18months; for Hodgkin disease was
30% at 18 months; and for aggressive non-Hodgkin
lymphoma was 25% at 18 months. Conclusions of
the study were that UCB transplantation is a valuable
alternative for patients with advanced lymphoma and
CLL. The most important prognostic factors were:
(1) indolent lymphoma; (2) chemosensitive disease;
(3) use of low-dose TBI in the conditioning regimen;
and (4) UCB units with higher cell doses.
An additional study compared outcomes after un-
related CBT and matched unrelated donor RIC trans-
plantation for lymphoid malignancies. Diagnoses of
the patients included indolent NHL, Hodgkin lym-
phoma, aggressive NHL, mantle cell lymphoma, and
CLL. MUD peripheral blood stem cell (PBSC) was
used for 284 patients, single CBT for 44 patients, and
double CBT for 31 patients. Conclusions of the study
were that there were no differences between UCBT
and MUD-PBSCT in: (1) NRM; (2) relapse or pro-
gression; (3) PFS; or (4) OS. Further conclusions
were that UCBTs had delayed neutrophil recovery
and a lower incidence of cGVHD.Session IV. Indications and Conditioning
Regimens for HSCT
Dr. Daniel Weisdorf reviewed current indications
for hematopoietic cell transplants in adults with hema-
tologic malignancies and the role of CBT. Experience
in CBT indicates that in adults graft failure, which
occurs in 10%, is still limiting. In CBT, moderate to
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is uncommon. There is less cGVHD, and it is more
responsive to therapy. Earlier discontinuation of im-
munosuppression is feasible, and there is a lesser
need for medical interventions from day 100 to 1
year. Costs are higher with CBT than with matched
unrelated donors because of graft failures and costly
supportive care. UCB transplants provide graft-
versus-leukemia (GVL) effect as evidenced by the
fact that the relapse rate is the same with single UCB
as with BMT or PBSC transplants. With CB trans-
plants, the GVL is not tied to GVHD. There is less
relapse with double UCB compared with matched sib-
ling, matched unrelated donor, and mismatched unre-
lated donor transplants (P\.01). Disease-free survival
(DFS) is the same with these various donor sources for
HSC (P 5 .19). KIR B/x genotype donors confer im-
proved relapse-free survival in AML unrelated donor
HSCT. Studies should take place regarding UCB se-
lection, includingpermissiveHLAmismatches, the sig-
nificance of KIR genotype and noninherited maternal
antigens, and the HSC content and functional capacity
of CB units. Other studies should address improving
UCB engraftment by improving homing and adhesion
to the HSC niche or by ex vivo expansion of HSC or
committed progenitors. Improvements should be
made in specialized supportive care for UCB HCT to
address the question ofmore prolonged or different an-
tibiotic therapy for infections, and smarter and more
economical transfusion support. Important studies
are needed to compare haploidentical mismatched
transplants with URD transplants, and to find ways to
reduce morbidity (infections, GVHD, transfusions,
duration of specialized HCT care, and quality of life).
Dr. Vanderson Rocha discussed CBT using myeloa-
blative and RIC regimens. The ideal preparative
regimen for marrow transplantation of patients with
malignant diseases should be capable of eradicating
malignancy, have tolerable morbidity without mortal-
ity, and have sufficient immunosuppressive effect to
avoid graft rejection. No ideal preparative regimen
currently exists. There is a continuum between fully
nonmyeloablative and RIC regimens. A risk factor
analysis has been carried out regarding neutrophil re-
covery and mortality after single-unit UCBT using
myeloablative conditioning regimen for patients with
malignant disorders. The patients (n 5 1946) were
transplanted with a single-unit UCBT from 1994 to
2009 for malignant disorders after a myeloablative
conditioning regimen. Multivariate analysis for neu-
trophil recovery indicated that significant factors
were the number of CD341 cells, HLA compatibility,
use of fludarabine, use of prophylactic HGF, and
remission status of the disease. For platelet recovery,
significant factors were the number of CD341 cells,
use of fludarabine, use of prophylactic HGF, and
transplant year .2004. A study of RIC regimen aftersingle unrelated CBT for adults with hematologic ma-
ligancies (n 5 176) indicated that significant factors
were the type of conditioning (FLU 1 EDX 1 TBI)
(hazard ratio [HR] 5 0.53; P\.001) and early and in-
termediate phase of the disease (HR 5 0.63; P 5 .02).
A study was carried out comparing RIC regimen versus
myeloablative conditioning (MAC) CBT for adults
with acute leukemia (a registry-based retrospective
analysis). There were 107 RIC patients and 403
MAC patients. Results indicated that in the MAC reg-
imen the addition of fludarabine is associated with
myeloid recovery after single-unit CBT. However, it
is associated with better survival only in patients trans-
planted in remission.
RIC regimen (CY 1 FLU 1 TBI) is associated
with better results in retrospective analysis. RIC is as-
sociated with decreased NRM but higher relapse inci-
dence in adults with acute leukemia when compared to
MAC. Approaches that decrease the incidence of re-
lapse after RIC may improve outcomes.
Dr. Navneet Majhail discussed RIC for CB trans-
plants in older patients. Hematologic cancers are
common in the elderly. Challenges to HCT in older
patients include the fact that older AML patients are
more likely to have unfavorable cytogenetics, multi-
drug resistance, a poor performance status, and comor-
bidities. Also, suitable sibling donors are less frequently
available. RIC may alleviate some of these problems. A
recently published study has indicated that using RIC,
old age has no adverse impact on HCT outcomes. The
study concerned 1080 patients with AML complete
remission 1 (CR1) and MDS of various ages: 40-54
(n 5 409), 55-59 (n 5 295), 60-64 (n 5 258), and
$65 (n 5 118) years. In all of these age groups, the
NRM and DFS were similar using related and unre-
lated donors. A prospective study has compared the
outcomes of UCB transplants versus matched related
donor (MRD) HCT in patients 55 to 70 years old.
Forty-seven had MRD transplants, and 43 had UCB
transplants (88% received 2 CB units). The 3-year
PFS, 3-yearOS, and the 1-year transplant-relatedmor-
tality (TRM)were all similar in the 2groups.Donor en-
graftment at day 42 was 100% with MRD transplants
and 89%withUCB transplants. Grade III-IV aGVHD
was 49% with UCB transplants and 23% with MRD
transplants, but cGVHD at 2 years was 43% with
MRD transplants and only 17%withUCB transplants.
Take-home points are that UCB is an alternative graft
source for older patients who do not have MRD. Co-
morbidities should be carefully reviewed when choos-
ing older patients for transplantation. Also, RIC UCB
HCT in older patients needs further investigation.
Dr. Mitchell S. Cairo discussed reduced toxicity
conditioning (RTC) compared to MAC prior to
UCBT in pediatric recipients. A study was performed
to test the hypothesis that RTC versus MAC prior to
UCBT in pediatric recipients will be associated with
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increase in OS. Eighty-eight patients were studied
(RTC5 39 and MAC5 49; 24 RTC patients had ma-
lignant disorders as did 34 MAC patients). The prob-
ability of myeloid engraftment was similar, platelet
recovery (.20,000) was better in the RTC group.
Grade III-IV aGVHD was higher in the RTC group,
and there was no difference in incidence of cGVHD.
TRM at 100 was 35% in MAC, whereas it was only
2.5% in patients with RTC. The probability of OS
was significantly better with RTC than with MAC at
8 to 9 years posttransplant (P 5 .0032). In summary,
the risk of day 100 NRM following UCBT in pediatric
recipients was significantly increased by MAC com-
pared to RTC. The probability of OS following
UCBT in pediatric recipients is significantly decreased
by MAC and in patients with low CD34/kg cell dose.
The probability of grade II-IV aGVHD following
UCBT in pediatric recipients is significantly increased
following MAC versus RTC. A prospective, random-
ized multicenter trial with a larger cohort with specific
regimens and diseases/status will be needed to confirm
these preliminary findings.Session V. New Concepts in Donor-Recipient
Matching for CB Transplants
Dr. Andromachi Scaradavou presented data regard-
ing the role of noninherited maternal HLA antigens
(NIMA) in CB transplantation and implications for
search and unit selection. Fetal exposure to NIMA
produces tolerance and has been shown to have a
favorable effect in solid organ and related SCT. A
study was done to test the hypothesis that reexposure
of CB cells to NIMA will affect transplant outcomes.
A retrospective analysis was carried out in patients
with hematologic malignancies (n 5 1121) who re-
ceived single-unit CB grafts having 0, 1, or 2 HLA-A,
-B, -DRB1 mismatches. Conclusions of the study were
that matching for the donor’s NIMA can improve out-
come in unrelated CB transplantation. There is faster
engraftment, even in grafts with low TNC dose,
improved TRM even in adolescents/adult patients,
no increased risk of aGVHD or cGVHD, and possibly
reduced relapse rates in patients with myeloid
malignancies. Therefore, HLA-mismatched, NIMA-
matched CB units can be the graft of choice for
patients with hematologic malignancies lacking fully
matched donors. Further conclusions are that includ-
ing the NIMA matches in the search algorithm
increases substantially the probability of finding opti-
mal CB grafts for patients. In cases where only HLA-
mismatched CB units can be identified, review of the
maternal HLA typing of these units may allow select-
ing a NIMA-matched CB graft. Obtaining maternal
HLA typing is an efficient way of expanding many-
fold the current global CB Inventory.Dr. Jeffrey Miller discussed KIR genotyping—
thinking beyond HLA for donor choice. Two pub-
lished studies have reached somewhat different
conclusions regarding the significance of killer-
immunoglobulin receptor (KIR) genotyping in
HSCT. A study was performed to determine whether
donorKIRcorrelateswith clinical outcomes.The strat-
egywas to determinewhether evaluation of KIRB hap-
lotypes for specific gene motifs will inform selection
of ‘‘good’’ KIR donors to improve the effectiveness of
unrelated donor HCT. The study cohort consisted of
1409 donor/recipient pairs from URDHCT for acute
leukemia. The results of the study indicated that favor-
able KIR donors are beneficial in T cell–replete and
T cell–depletedHCT.This benefit is from relapse pro-
tection. There is benefit of some KIR B haplotypes in
protecting against GVHD. A prospective plan in
URD transplant to choose donors will start in 2010.
Dr. Juliet Barker discussed the combined effect of
total nucleated cell dose and HLA matching on trans-
plant outcome in 1061 CB recipients with hematologic
malignancies, and the implications for unit selection.
Initial analysis indicated that neither TNC dose nor
HLA match had any association with relapse risk,
but both affected TRM; TRMwas the major endpoint
of the combined TNC and HLA-match analysis. A
study was performed on the influence of cell dose
and HLA match on double-unit engraftment (n 5
84). All patients had hematologic malignancies; 61 pa-
tients received ablative conditioning, and 23 received
nonablative conditioning. Results indicated that the
TNC dose is a critically important determinant of en-
graftment, TRM, and survival. HLA match is a criti-
cally important determinant of engraftment, GVHD,
TRM, and survival. An effect on TRM postengraft-
ment is evident even if there is no GVHD. The best
outcome is associated with 0 mismatches (MM) (ie,
6/6 units) without dose effect to date; 6/6 CB unit re-
sults may rival 10/10 URD. A better match can com-
pensate for a lower dose so that a sliding scale should
be used with unit selection: the less well matched the
unit, the bigger the required dose (this is not possible
in adults). One should avoid single units with 1-2 mis-
matches and\2.5  107/kg. In double CBT, there is
an increased chance of transplanting at least 1 unit of
good quality, plus unit versus unit effects may augment
engraftment and reduce relapse. In selection of CB
units, the TNC should be above 2.0  107/kg, and
HLAmatching should be$4/6 A,B antigen, DRB1 al-
lele. Within a given match grade, the largest unit
should be chosen. Also consider the bank of origin
(speed, reliability, quality). The same rules apply to se-
lecting units 1 and 2. The unit–unit HLA-match crite-
ria should be abandoned.
Dr. Cladd Stevens discussed HLA mismatch and
mismatch direction in CBT. The hypothesis is that
the direction of HLA mismatch affects outcome. In
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one would expect decreased engraftment, decreased
GVHD, and decreased GVL (increased relapse). In
the GVH direction. One would expect improved en-
graftment, increased GVHD, and persistence of
GVL. In the present study, the type of the mismatch
and the number of mismatches were considered. The
analysis concerned 1202 transplants that were carried
out primarily for hematologic malignancies (72%).
The number of transplants with the various types of
mismatches (MM) were as follows: No MM, 72;
1 MM bidirectional, 364; 2 MM bidirectional, 525;
1 MM GVH only, 51; 2 MM GVH only, 7; 1 MM
rejection (Rej) only, 30; 2 MM rejection only, 10;
2 MM (2 GVH, 1 Rej), 83; 2 MM (2 Rej), 1 GVH, 54;
and 2 MM (1 GVH 1 1 Rej, 5). The outcome of the
study was as hypothesized, that is, rejection-only mis-
matches have a trend for decreased engraftment, a trend
for increasedGVHD, an increase in relapse, a trend for
increased TRM and overall mortality, and a trend for
decreasedDFS.GVH-onlymismatches have increased
engraftment, no increase inGVHD compared to other
MM transplants, a trend for decreased relapse, a de-
crease in TRM and overall mortality, and an increase
in DFS. There were no effects in mixed direction
transplants. Therefore, recommendations for CBU
selection are that rejection-only mismatches should
be avoided, especially in hematologic malignancies.
GVH-only mismatches are preferred. They are as
good as 0-mismatched CBUs, especially in hemato-
logic malignancies, and there is no increase in GVHD.Session VI. Engraftment of CB Stem Cells
Dr. Maruisz Z. Ratajczak discussed novel strategies
to enhance homing and engraftment of CB stem cells.
Current strategies to accelerate hematopoietic recon-
stitution after transplantation include transplantation
with larger numbers of HSPCs or ex vivo expansion
of harvested HSPCs before transplantation. However,
the number of HSPCs available for allogeneic or
autologous transplantation is often low, and current
strategies to expand HSPC ex vivo are unfortunately
inefficient. Complement cascade cleavage fragments
such as C3a enhance the homing responses of HSPCs
to SDF-1 gradient. Also, antimicrobial peptides
(AMPs) are host defense peptides and are an evolution-
arily conserved component of the innate immune
response. Priming of UCB HSPCs homing is a new
strategy to accelerate engraftment. Conclusions
reached after study of these homing agents are that
the complement component fragments as well as small
granulocyte-derived cationic peptides that primarily
possess antimicrobial functions and are harmless to
mammalian cells increase/prime responsiveness of
HSPCs to SDF-1 gradient. Their presence in leuko-
pheresis products may explain why mobilized PBSCblood engrafts faster than BM. Cationic peptides could
be employed to prime ex vivo HSPCS before trans-
plantation and enhance/accelerate their engraftment.
Dr. Colleen Delaney discussed Notch-mediated ex-
pansion of human CB progenitor cells capable of rapid
myeloid reconstitution. A number of studies have indi-
cated that there is delayed engraftment in CBT com-
pared with sibling donor or matched unrelated donor
transplants. The goal of the present work is to provide
cells that rapidly engraft and overcome the delay in he-
matopoietic recovery following transplantation with
CB. Culture with engineered Notch ligands enhances
the magnitude and kinetics of marrow repopulation in
NOD/SCID mice. A study in patients was done to ex-
amine the safety with infusion of ex vivo–expanded CB
cells generated via culture in the presence of engi-
neered Notch ligand. Increased absolute numbers of
CD341 cells are reliably generated via Notch-
mediated ex vivo expansion. The study examined the
kinetics and durability of hematopoietic reconstitution
and the relative contribution to engraftment as pro-
vided by the expanded and unmanipulated CB grafts.
Unmanipulated units provided a mean of 2.4 CD341
cells, whereas the expanded units averaged 60.3
CD341 cells/kg. Data are now available for 11 patients
who received expanded CD341 cells. Results indicate
that there is a significantly reduced time to absolute
neutrophil count (ANC) .500 in patients receiving
ex vivo–expanded cells (14.5 days) compared to con-
ventional double CB transplants (26 days). Conclu-
sions to date are: (1) Notch-mediated ex vivo
expansion of CD341CB progenitors is clinically feasi-
ble, resulting in a significant increase in the absolute
number of CD341 cells from a single unit of CB; (2)
infusion of the expanded cell product has not resulted
in any toxicities; (3) the expanded cells contribute to
rapid early myeloid engraftment; and (4) in some cases,
the expanded cells have persisted in vivo, suggesting
that there may be long-term repopulating ability of
the expanded cell product.
Dr. Manuel N. Fernandez reviewed the use of adult
third-party donor cells to improve outcome of single-
unit CB transplants. The objective of the ‘‘Dual Trans-
plant’’ strategy is to produce a ‘‘bridge graft’’ to reduce
problems inherent in late engraftment. The dual trans-
plant strategy utilizes myeloablative conditioning
and coinfusion of T-depleted mobilized HSC from
a third-party donor (TPD). To date, 55 patients have
been studied who had high-risk hematologic diseases.
Results indicate that there is a short posttransplant
neutropenia with early and transient engraftment of
the TPD HSC (the ‘‘bridge graft’’), there is a high
rate of full CBT chimerism, and a low morbidity and
mortality because of neutropenia-related infections.
There is also favorable OS and DFS, not worse than
those of HLA-identical family donors, and a relatively
low cost. Possibilities for the future include the
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improve outcomes of unrelated CBT, for example,
MSC, NK cells, CTLs, T-regs, and gd-T cells.
Dr. Jonathan Gutman discussed single-unit domi-
nance following double-unit CBT and indicated that
CD81 T cells are associated with the development
of single-donor dominance. Clinical observations re-
garding double-unit CBT indicate fewer graft failures
in adults and large children; lower TRM in adults
and large children; possible decreased relapse; more
(at least mild/moderate) aGVHD; and the fact that
1 unit wins. The reason that 1 unit wins is unclear.
The reasons are probably multifactorial. An hypothe-
sis has been developed that the process is immune me-
diated, that is, that the winning unit rejects the losing
unit. A study was developed to investigate the potential
role of T (andNK) cells. 14 patients have been studied,
5 receiving 2 unmanipulated units and 4 patients re-
ceived 1 CD341–selected and ex vivo–expanded unit
and 1 unmanipulated unit. Ten patients developed
rapid (by day 28) single donor chimerism, 3 had persis-
tent mixed chimerism, and 1 had graft failure. In
patients with a single-donor dominant cell, there was
interferon (IFN)-g–secreting cells reactivity against
cells of the losing unit but not against cells of the win-
ning unit in most patients, whereas in patients with
persistent mixed chimerism, no such reactivity could
be demonstrated. In summary, there is compelling ev-
idence that CD81 T cells contribute to emergence of
dominant units. There is no evidence of functional re-
sponses from CD41 or NK cells. It remains unclear
why 3 patients maintained mixed chimerism.Sessioni VII. Infections, Immune Reconstitution,
and Adoptive Immunotherapy after CBT
Dr. Catherine Bollard discussed expansion of CB-
derived antigen-specific T cells for clinical use. Fifteen
of 25 patients received donor-derived virus-specific
T-lymphocytes for viral infections after HSCT. In
13 of 15 patients, there was a decrease in viral load
with corresponding elevation in virus-specific cyto-
toxic T lymphocytes (CTL) detected in the peripheral
blood. No other antiviral therapy was required for 23
of the 25 patients. Investigations are being carried
out to determine whether virus-specific CTL can be
expanded from CB for adoptive immunotherapy to re-
store antiviral immunity and reduce viral infection
post-CB transplantation. Extensive experimentation
has indicated: (1) donor-derived multivirus-specific
CTL can prevent and treat viral infection after
HSCT; (2) virus-specific CTL can also be expanded
from na€ıve CB T cells; and (3) there is a need to
determine whether the CB-derived virus-specific
CTL will be as efficacious in vivo as peripheral blood–
derived CTL. Further conclusions are: (1) CB-derived
multivirus-specific CTL can be transduced witha CAR-CD19 to redirect specificity to B cell malignan-
cies; (2) functional CB-NK cells can also be expanded
from CB; and (3) there is a need to determine whether
the administration of CB-derived NK cells is feasible
and safe in patients after CB transplantation.
Dr. Juliet Barker reviewed infections and immune
recovery following double-unit CBT. A detailed
retrospective study of 72 patients transplanted for
hematologic malignancies indicated that: (1) bacterial
and fungal infections are common, but death from
these is quite unusual; (2) neutopenia following abla-
tive preparative regimens remains a challenge despite
a high sustained engraftment rate; (3) the best prophy-
laxis for bacterial infection is unclear; and (4) the
frequency of making a specific diagnosis in cases of
bacterial and fungal pneumonia is very low. Further,
(1) viruses are the greatest contributor to infectious
mortality, but lethal infections are limited to the first
4 months; (2) nonetheless, improved antiviral agents
for prophylaxis and treatment and augmentation of
antiviral immunity should be a priority; and (3)
Epstein-Barr Virus (EBV) viremia and adenoviral en-
teritis occurred exclusively in the context of GVHD
therapy or corticosteroids for another indication.
Finally, (1) there is an improved risk after day 120,
which is coincident with immune recovery; (2) plans
for more sophisticated measures of immune recovery
are underway, but ultimately, infection risk is the
best measure of immune recovery; and (3) these results
support improved infection mortality after ATG-free
double-unit CB transplants.
Dr. Paul Szabolcs discussed immune reconstitution
following CB transplantation. Death because of
infections is the primary cause of death in UCB trans-
plantation in the past and modern (.2002) era alike.
Most such deaths occur before 6 months posttrans-
plantation. CB is a unique graft source because of a
high frequency of highly proliferative primitive stem
cells paired with ‘‘na€ıve’’ lymphocytes. More robust
lymphocyte reconstitution is associated with lower
mortality after single-unit UCB transplantation if the
mean values are compared over a course of 2 years. En-
hanced lymphocyte reconstitution is a composite of B
cell, CD31T cell, and in particular, CD41 na€ıve T cell
recovery. If immune recovery is analyzed only from
data collected during the first year, B cell, T cell, and
even CD41 T cell recovery lack predictive power
even in univariate analysis. In contrast, in univariate
analysis, survival is superior in those with more rapid
recovery of recent thymic emigrants, Tregs, and plas-
macytoid dendritic cells during the first year. Declin-
ing activation state (HLA-DR expression) of CD81
T cells during the first year also predicts better survival
in the univariate model. In this pediatric dataset where
malignancy was the indication for 1/3 of UCBT, the
only parameter of lymphocyte and dendritic cell
reconstitution during the first year post-UCB
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tivariate analysis was the recovery of thymic function
measured by CD45RA1/CD62L2/CD41 subset.Session VIII. HSCT for Thalassemia and
HIV-Infected Patients
Dr. Gero H€utter discussed long-term control of
HIV by CCR5 Delta32/Delta32 SCT. A 40-year-old
man, who had known HIV infection since 1996 and
who was treated with highly active antiretroviral ther-
apy (HAART) since 2002, developed AML. Infection
with HIV requires the presence of a chemokine recep-
tor 5 (CCR5), and homozygosity for a 32-bp deletion
(delta32/delta32) in the CCR5 allele results in an inac-
tive CCR5 gene product, and consequently confers
high resistance against HIV-1 infection. The patient’s
potential donors were tested for the deletion, which
occurs in the homozygous state in about 1% of Cauca-
sians. This patient had a remarkably large number of
potential HLA-matched donors (232), and 1 such
donor was identified as homozygous for the deletion.
HSCT was carried out using PBSCs from this donor,
and engraftment was achieved 13 days after the
procedure. However, AML relapsed 332 days after
transplantation, necessitating a second transplant
from the same donor. The second procedure led to
a complete remission of the AML, which has remained
in remission. The patient has not received HAART
therapy since the first transplant was performed. The
patient’s HIV-1 load was measured with the use of
RNA and DNA PCR assays, and since day 61 follow-
ing the first transplant, serum levels of HIV-1 RNA
have remained undetectable. It is now 2 years and 4
months since the first transplant. In summary, alloge-
neic HSCT in patients with HIV is feasible, and a case
of allogeneic HSCT with a CCR5-D32 homozygous
donor highlights the decisive role of CCR5 in main-
taining HIV infection. More cases are necessary to
document the effectiveness of this procedure as are
attempts to translate this approach into a more
feasible way.
Dr. Lawrence Petz discussed an inventory of CB
units homozygous for the CCR5-D32 deletion for po-
tential cure of HIV infections. Investigators have the-
orized that HSCT using products obtained from
individuals homozygous for the CCR5-D32 allele
could provide therapeutic benefit for individuals with
HIV infections. The case report by H€utter et al. dem-
onstrated long-term control of HIV infection by
HSCT from an unrelated adult donor homozygous
for CCR5-D32. However, it is difficult to generalize
this approach because there are usually only a small
number of very well HLA-matched adult donors avail-
able for an individual patient, and there are very few
persons who are homozygous for the variant allele.
However, an inventory of umbilical CB units that arehomozygous for the CCR5-D32 allele could provide
an improved probability of finding an appropriately
HLA-matched donor for a patient with HIV infection
in need of a transplant. We have tested 6000 Cauca-
sian units in our CB bank to develop an inventory of
units homozygous for the CCR5-D32 allele and found
48 homozygous units. Projections of the probability of
HLAmatches within this special inventory using HLA
types of simulated Caucasian patients indicated a
0.04% probability of finding a 6/6 matched unit, a
14.23% for a 5/6 matched unit, and 54.4% probability
of a 4/6 matched unit. The median TNC dose of units
in the special inventory is 117.5  107 (range: 39-351),
which is adequate for patients up to 46 kg based on
a cell dose of 2.5  107 TNC/kg. However, it is emi-
nently feasible to test additional units so that develop-
ment of an inventory of at least 300 CCR5-D32
homozygous units can be accomplished. With an in-
ventory of 300 units, the probability of finding an
HLA-matched unit with a TNC of 2.5 107/kg in pe-
diatric patients is 0.01% for 6/6 matches, 10.58% for
5/6 units, and 73.61% for 4/6 matches. For adult pa-
tients, the probabilities are 0.01% for 6/6 matched
units, 4.49% for 5/6 matched units, and 27.92% for
4/6 matched units. Patients in need of an HSCT and
who are infected with HIV should be offered trans-
plantation with stem cells that are homozygous for
CCR5-D32, as should patients with an unsatisfactory
course on antiretroviral drug therapy.
Dr. Tang-Her Jaing presented data on transplanta-
tion of patients with transfusion-dependent thalasse-
mia. A study has been done in which 40 CBTs were
performed in 35 patients with a median age of 5.5 years
who had transfusion-dependent thalassemia. A double
CBTwas performed if no single UCB unit of adequate
cell dose was available. All donors were HLA-
compatible unrelated CB units that were selected
from the same NMDP-affiliated CB bank. CBUs
were matched at $4/6 HLA antigens based on
antigen-level HLA-A and B typing and allele-level
HLA-DRB1 typing. The preparative regimens con-
sisted of oral or intravenous busulfan, intravenous cy-
clophosphamide, and equine ALG. The median
number of nucleated cells infused was 7.8  107/kg
(range: 2.8-14.7) and CD341 was 4.0  105/kg (range:
1.7-19.9). Twenty-two patients were classified as Pe-
saro I, 11 were Pesaro II, and 2 were unclassified.
Twenty-eight of the 35 patients have become transfu-
sion independent and achieved hematopoietic recon-
stitution after the first transplant. Five patients
subsequently underwent retransplantation for graft
failure. None required rescue with cryopreserved au-
tologous back-up harvests. Acute GVHD was grade I
in 6 patients, grade II in 12, grade III in 15, and grade
IV in 1. Fourteen patients developed chronic skin
GVHD, which was was extensive in 1 and limited in
13. The 5-year OS and thalassemia-free survival were
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dence of TRM at 2 years was 11.7%. Of these patients,
83% were alive and transfusion independent with
a Lansky performance score of $80% achieved be-
tween 6 and 76 months posttransplant (median, 36
months). The conclusion was that this is the largest
single institution report of unrelated CBT for
transfusion-dependent thalassemia and shows the fa-
vorable clinical results that are attainable when TNC
dose is optimized with CB units, when no postthaw
wash is performed, and when double CBT is utilized
when necessary.Session IXA. CB Banking
Dr. Ellen Lazarus discussed CB licensure. With
publication of hematopoietic progenitor cells, cord
(HPC-C) guidance documents, the Food and Drug
Administration (FDA) also announced that the
phase-in implementation period for Investigational
New Drug (IND) and Biologic Licensure Application
(BLA) requirements for these products will end onOc-
tober 20, 2011 (2 years after date of publication). Spon-
sors are encouraged to send in IND and BLA
applications as soon as possible. The HPC-C Licen-
sure Guidance provides recommendations to manu-
facturers applying for licensure of minimally
manipulated, unrelated allogeneic placental/umbilical
CB, for specified indications. Information contained
in the HPC-C Licensure Guidance includes how to
use the Guidance when applying for a BLA, applicable
regulatory requirements and the license application
procedure. Licensure may apply to HPC-C previously
manufactured using the same procedure where docu-
mentation is provided. Licensure may also apply to
HPC-C in inventory that were previously manufac-
tured using different procedures provided that the
manufacturer submits a separate validation summary
and includes data demonstrating comparability of pre-
viously manufactured HPC-C to the currently manu-
factured HPC-C, and providing evidence that
methods, facilities, and controls used for manufacture
were compliant with CGMPs. The scope of the guid-
ance was changed to expand the list of intended clinical
uses for the HPC-C covered by the Guidance based on
public comment and additional data submitted to the
docket. The Establishment Description section on
Computer Systems includes more information about
resources for information on software regulation and
validation. Also, references and footnotes have been
updated. Draft CB IND Guidance was published for
comment in October 2009. An IND is necessary for
2 reasons: (1) a product that does not conform to all
BLA requirements (an unlicensed HPC-C) may be
the best product from a clinical standpoint; or (2) the
clinical use of the HPC-C may be for an indication
other than those defined in the Guidance document.Dr. Michael Boo discussed the use of INDs for non-
licensed CB units and the potential role that NMDP
may have in facilitating these procedures. Draft
guidancewas issued onOctober 20, 2009, as a compan-
ion to the BLA guidance. The IND is intended to pro-
vide access to CB units that will not meet license
requirements or for indications other than those spec-
ified in the document. The comment period has
expired, and the industry is now waiting for final guid-
ance. The INDwill cover CBUs that are used for min-
imally manipulated units intended for hematopoietic
reconstitution in recipients unrelated to the donor
for hematologic malignancies, certain lysosomal stor-
age diseases, primary immunodeficiency diseases, BM
failure, and beta thalassemia. Sponsors include CB
banks for units from the bank; registries for units ac-
cessed through the registry; and transplanters for units
used in transplantation of patients. Sponsors are re-
quired to submit IND safety reports and annual re-
ports, to ensure that licensed physicians are qualified
to administer the investigational drug, to provide
licensed physicians with the required information, to
maintain an effective IND with respect to the investi-
gations, and to maintain adequate drug disposition re-
cords. Investigators must report adverse drug events to
the sponsor, ensure that the informed consent require-
ments are met, ensure that institutional review board
review of the use of the HPC-Cs under the IND is ob-
tained, and maintain accurate case histories and drug
disposition records. Transplant center responsibilities
are to designate a principal investigator, submit a pro-
tocol to their institutional review board, obtain re-
search consent from CBU recipients, to continue to
report outcomes data to the Center for International
Blood and Marrow Transplant Research (CIBMTR)
and report adverse events to National Marrow Donor
Program (NMDP) and collaborate in investigations of
events. International CB banks must be registered with
the FDA, preferably with accreditation by AABB or
Netcord-FACT, to report adverse events to the
NMDP and collaborate in investigations of events,
and must comply with NMDP procedures for estab-
lishing donor eligibility.
Loren Gragert presented data regarding estimating
match rates with adult donors and umbilical CB units
in the NMDP ‘‘Be the Match’’ Registry. Past analyses
have been limited because of little or no high-
resolution haplotype data, only 4 racial/ethnic groups
(Caucasian, African American, Asian, and Hispanic),
little or no data on generally acceptable mismatches
and limited consideration of CB units. Present analy-
ses include extensive high-resolution 4-locus haplo-
type frequencies within each racial/ethnic group, 21
racial/ethnic groups, stringent matching according to
currently accepted standards for CB and adult units,
more thorough consideration of CB, and incorpora-
tion of adult donor availability and umbilical CB unit
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including 8/8 allele (or 7/8 and 6/8 allele) available-
match rates in the adult donor registry; adult or pedi-
atric cord match rates in the CB registry with a cell
dose of $2.5 TNC/kg; ‘‘8/8 adult then cord’’ match
rates for adult or pediatric patients, considering avail-
ability and dose; ‘‘cord only’’ match rates for adults or
for pediatric patients, considering availability and
dose; and the increase in match rates with increasing
the inventory of adults in the registry or CB units.
The data obtained from the analysis are valuable re-
garding the 4 approaches that will compete for avail-
able resources: (1) adult donor recruitment; (2) CB
unit ‘‘recruitment’’; (3) adult donor retention/avail-
ability; and (4) clinical research to improve results
with suboptimal adult or CB units.Session IXB. CB Banking
Dr. Kevin Shoulars discussed predicting potency of
CBUs with enumeration of ALDH bright (ALDHbr)
cells. CFUs provide a useful potency assay but the use-
fulness of the assay is limited by the time required (14
days) and variability among laboratories. Alternatives
are a shorter CFU assay (5-7 days), a HALO assay
that measures ATP produced by dividing cells after 5
days, and an assay for ALDHbr cells. A retrospective
study of 38 CBUs used for transplantation indicated
that rapidly engrafting units could be distinguished
from nonengrafting units using CFU-infused dose or
ALDHbr-infused dose. A prospective trial with the
NMDP and CIBMTR is planned. Clinical outcomes
of 800 transplants (600 single unit and 200 double
unit) will be analyzed prospectively to evaluate data
from ALDHbr and CFU to determine their ability to
predict engraftment.
Dr. William Miller discussed the stability of CB
cells after processing and storage. Experience has
been gained in over 700 transplants using RBC-
reduced and plasma-reduced units, some of which
are washed at the transplant center, although the latter
procedures are not well standardized. A study of units
transplanted after various numbers of years of storage
indicated that the engraftment rate is essentially the
same using units stored up to 12 years prior to
transplantation. Further, the CB unit age does not
impact the probability of or time to patient neutrophil
recovery.
Dr. Joanne Kurtzberg discussed, ‘‘Thawing and in-
fusion of CB units; gaining knowledge to prevent
adverse infusion events.’’ Over the past several years,
increased emphasis has been placed on producing
a high-quality CBU, but much less attention has
been paid to the end user of the CB. Issues are that
CB products and thawing are complex, there is a lack
of standardization of thawing methods, new centers
do not receive formal training, thawing proceduresprovided by banks are inconsistently followed by trans-
plant centers, and there is need for improved compre-
hensiveness of safety monitoring. At the transplant
centers, the temperature of the CB unit must be con-
firmed, the product must be inspected for labeling,
the integrity of the bag determined, and the unit
must be transferred to a liquid nitrogen freezer.
Methods of thawing and infusion include direct infu-
sion, dilution prior to infusion, or dilution with wash-
ing before infusion. Such issues are being highlighted
because a few serious infusion reactions in recipients
of double CB units have been reported in the past
few months. Problems with CBU thawing have also
been reported from a few laboratories, and there is
a lack of ‘‘CB thaw preparedness’’ at transplant centers
in general. A list of things that can be done are as fol-
lows: (1) formalize guidelines for single- and double-
cord infusions; (2) require transplant centers to
validate a thaw/wash and wash procedure or to follow
the procedure provided by the bank; (3) ask accrediting
agencies to create additional standards for CB thawing
and administration; (4) improve centralized reporting
and review of infusion-related adverse reactions,
(5) create a training program for CB thawing; (6) re-
quire transplant centers to practice a thaw of a RBC-
reduced and RBC-containing CBU before handling a
patient sample; (7) consider a randomized trial of thaw
versus thaw and wash; and (8) recommend that trans-
plant centers identify a backup unit in advance of the
transplant.
Dr. John McMannis discussed preparation of CB
units for reinfusion. In the manual procedure that
has been used, one thaws the unit, transfers to a 150-
to 600-mL transfer pack, dilutes with 10%Dextran40,
dilutes with 5% human serum albumin, fills the bag
with 10% Dextran40, incubates 5 minutes, centri-
fuges, removes the supernatant, and resuspends the
cells. TNC recovery has been 84% during the last
4 years, and viability of CD341 cells has been .90%
both postthaw and postwash. Analysis of cell recov-
eries from units from 33 banks indicated that TNC re-
covery from almost all CB banks was highly consistent,
in the range of 80% to 85%. A trial of an automated
procedure suggests that there are advantages over the
manual method in that there are fewer interventions
and there is reduced time for processing and improved
reproducibility. TNC recoveries from volume-
reduced CBUwere similar using the automated proce-
dure. Also, TNC recoveries from plasma-reduced
units were lower using the automated procedure al-
though viability of CD341 cells was .95%.
Donna Regan indicated that a reconstitution proto-
col was developed and validated for units stored after
RBC-reduced process methods. An hypothesis sug-
gested that a simple 1:1 dilution without centrifuga-
tion would stabilize the product, reduce the DMSO
concentration by 50%, and allow for a controlled
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A study was performed with CB units that were
removed from liquid nitrogen storage and thawed in
a 37C water bath. They were split into 3 fractions.
One fraction was left unmanipulated to mimic the bed-
side thaw. The other 2 fractions were diluted with an
amount of albumin/dextran solution equal to the
volume of product (1:1), resulting in a 5% DMSO
concentration. The final third of the product was
then centrifuged at 1200 rpm (400  g) for 20 minutes
and supernatant expressed. All were held at room
temperature and analyzed at the following time points:
immediately (time zero), at 2-hour intervals for the
first 8 hours, and at 24, 32, and 48 hours postthaw.
Results indicated that throughout the entire evalua-
tion, traditional wash and dilution methods performed
equally well with no significant differences observed in7AAD viability, TNC, CD34, or CFC recovery. An
additional study indicated that for 163 patients in
which diluted products were administered, similar
time to engraftment was observed when compared to
historic experiences with traditional wash and direct
infusion, and that there was no difference in probabil-
ity of time to neutrophil recovery (P . .05) between
the 3 methods. The conclusion was that the wash
method, intended to remove DMSO, RBC stroma,
and plasma postthaw, is not necessary when UCB
products are RBC- and plasma-reduced before cryo-
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